Literature DB >> 30380426

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.

Joseph Nacson, John J Krais, Andrea J Bernhardy, Emma Clausen, Wanjuan Feng, Yifan Wang, Emmanuelle Nicolas, Kathy Q Cai, Rossella Tricarico, Xiang Hua, Daniela DiMarcantonio, Esteban Martinez, Dali Zong, Elizabeth A Handorf, Alfonso Bellacosa, Joseph R Testa, Andre Nussenzweig, Gaorav P Gupta, Stephen M Sykes, Neil Johnson.   

Abstract

Entities:  

Year:  2018        PMID： 30380426      PMCID： PMC6296467          DOI： 10.1016/j.celrep.2018.10.009

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


× No keyword cloud information.
Due to an error in the production process, Table 1 contained two errors. In the second row of the table, Brca1+/+ was incorrectly labeled as Brca1ΔC/ΔC, and Brca1+/ΔC was incorrectly labeled as Brca1+/+. These errors have been corrected, and the revised version of Table 1 now appears with the paper online. The production team apologizes for this error.
  8 in total

Review 1.  PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer.

Authors:  Devashish Desai; Pushti Khandwala; Meghana Parsi; Rashmika Potdar
Journal:  Med Oncol       Date:  2021-04-23       Impact factor: 3.064

2.  PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.

Authors:  Jae Jin Kim; Seo Yun Lee; Ji-Hye Choi; Hyun Goo Woo; Blerta Xhemalce; Kyle M Miller
Journal:  Mol Cell       Date:  2020-09-22       Impact factor: 17.970

Review 3.  Moving Mountains-The BRCA1 Promotion of DNA Resection.

Authors:  Ruth M Densham; Joanna R Morris
Journal:  Front Mol Biosci       Date:  2019-09-03

Review 4.  A decade of clinical development of PARP inhibitors in perspective.

Authors:  J Mateo; C J Lord; V Serra; A Tutt; J Balmaña; M Castroviejo-Bermejo; C Cruz; A Oaknin; S B Kaye; J S de Bono
Journal:  Ann Oncol       Date:  2019-09-01       Impact factor: 32.976

Review 5.  New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.

Authors:  Ye Han; Xiaopeng Yu; Shuqiang Li; Ye Tian; Caigang Liu
Journal:  Front Oncol       Date:  2020-11-25       Impact factor: 6.244

6.  Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways.

Authors:  Cinzia Caggiano; Francesca Cavallo; Teresa Giannattasio; Gioia Cappelletti; Pellegrino Rossi; Paola Grimaldi; Darren R Feldman; Maria Jasin; Marco Barchi
Journal:  Cancers (Basel)       Date:  2021-02-13       Impact factor: 6.639

Review 7.  Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.

Authors:  Evthokia A Hobbs; Jennifer K Litton; Timothy A Yap
Journal:  Expert Opin Pharmacother       Date:  2021-07-26       Impact factor: 4.103

Review 8.  To Join or Not to Join: Decision Points Along the Pathway to Double-Strand Break Repair vs. Chromosome End Protection.

Authors:  Stephanie M Ackerson; Carlan Romney; P Logan Schuck; Jason A Stewart
Journal:  Front Cell Dev Biol       Date:  2021-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.